Achieve Life Sciences Inc. shares ACHV dropped 25% premarket on Tuesday as analysts forecasted delays in the launch of the company’s smoking cessation treatment cytisinicline. In a recent meeting with the U.S. Food and Drug Administration, the agency said it would need longer-term data beyond 12 weeks to assess potential safety risks of cytisinicline, given that the regulator views smoking cessation drugs as products for chronic, intermittent use, Achieve Life Sciences said in a regulatory filing Monday. The FDA’s questions suggest delays in Achieve’s filing of a new drug application for the treatment,…
To read the full article please click HERE
Credit: Source link